NeuroBioMat (NBM), a medical technology company that has developed an implantable medical device focusing on spinal cord repair using tissue engineering techniques, has been accepted in the U.S. FDA's Total Product Lifecycle Advisory Program (TAP) for its SPINEREP technology. This program is open to breakthrough devices early in the development process by guiding them through the entire product lifecycle, ensuring regulatory compliance and market adoption. The FDA has previously acknowledged SPINEREP technology, granting it Breakthrough Designation Technology status. NBM remains committed to advancing SCI treatment and to make a significant impact on spinal cord-injured patients’ lives.
